**Core Concept:**
Dravet's syndrome is a rare and severe form of epilepsy that typically presents in early childhood. It is a genetic disorder caused by mutations in SCN1A, encoding the voltage-gated sodium channel α1 subunit. The orphan drug status is a regulatory classification granted to drugs targeting rare diseases with fewer than 200,000 patients in the United States.

**Why the Correct Answer is Right:**
The correct answer, D. Levetiracetam, is an antiepileptic drug (AED) that is used as a treatment option for various types of epilepsy, including Dravet's syndrome. Levetiracetam works by binding to synaptic vesicle protein 2A (SV2A) and inhibiting the release of neurotransmitters, particularly glutamate. Due to its effectiveness in treating Dravet's syndrome, Levetiracetam has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for this indication.

**Why Each Wrong Option is Incorrect:**
A. Valproic acid (VPA) is another antiepileptic drug commonly used in the treatment of epilepsy. However, it does not specifically target Dravet's syndrome.
B. Lamotrigine (LTG) is also an antiepileptic drug but has not been specifically approved for the treatment of Dravet's syndrome.
C. Levetiracetam is the correct drug and has been granted orphan drug status for the treatment of Dravet's syndrome, making this option incorrect.

**Clinical Pearl:**
Orphan drug status for a specific disease indicates that the drug is effective and beneficial for that particular condition, providing confidence to healthcare professionals to prescribe the drug for that indication. In the case of Levetiracetam, its orphan drug status for Dravet's syndrome highlights its effectiveness and safety profile in treating this rare and severe epilepsy syndrome.